Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings
{{output}}
In Japan, the production of Leuplin®, a key drug for the treatment of prostate cancer and breast cancer, was temporarily suspended in 2020 by the manufacturer. The incident illustrated several significant failings, namely the lack of uniformity in internation... ...
